Literature DB >> 10438568

Characterization of an antibody that can detect an activated IGF-I receptor in human cancers.

M Rubini1, C D'Ambrosio, S Carturan, G Yumet, E Catalano, S Shan, Z Huang, M Criscuolo, M Pifferi, R Baserga.   

Abstract

The type 1 insulin-like growth factor receptor (IGF-IR) plays an important role in malignant transformation and in apoptosis. Its role in human cancer has now been firmly established. IGF-IR signaling occurs only when the receptor is activated by its ligands, which induce autophosphorylation of the receptor at several tyrosine residues. Although the IGF-IR (phosphorylated or not) can be detected in human cancers with conventional antibodies, it would be desirable to obtain antibodies that can detect the IGF-IR only when activated by its ligands. We describe and characterize in this paper such an antibody and show that it can be used in sections of human cancers to detect an autophosphorylated IGF-IR. This antibody will be useful in detecting autocrine or paracrine influences on normal and tumor cells and could eventually be also useful in diagnostic and prognostic studies of human primary and metastatic cancer. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10438568     DOI: 10.1006/excr.1999.4562

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  5 in total

Review 1.  Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology.

Authors:  James W Mandell
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

2.  IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

Authors:  Victoria Tovar; Clara Alsinet; Augusto Villanueva; Yujin Hoshida; Derek Y Chiang; Manel Solé; Swan Thung; Susana Moyano; Sara Toffanin; Beatriz Mínguez; Laia Cabellos; Judit Peix; Myron Schwartz; Vincenzo Mazzaferro; Jordi Bruix; Josep M Llovet
Journal:  J Hepatol       Date:  2010-02-13       Impact factor: 25.083

3.  Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02).

Authors:  Xabier García-Albéniz; Vicente Alonso; Pilar Escudero; Miguel Méndez; Javier Gallego; Jose Ramon Rodríguez; Antonia Salud; Julen Fernández-Plana; Hermini Manzano; Montserrat Zanui; Ester Falcó; Jaime Feliu; Mireia Gil; Carlos Fernández-Martos; Uriel Bohn; Carmen Alonso; Verónica Calderero; Federico Rojo; Miriam Cuatrecasas; Joan Maurel
Journal:  Oncologist       Date:  2019-06-24

Review 4.  IGF-IR in neuroprotection and brain tumors.

Authors:  Elisa Gualco; Jin Ying Wang; Luis Del Valle; Katarzyna Urbanska; Francesca Peruzzi; Kamel Khalili; Shohreh Amini; Krzysztof Reiss
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01

Review 5.  Lessons to Learn for Adequate Targeted Therapy Development in Metastatic Colorectal Cancer Patients.

Authors:  Helena Oliveres; David Pesántez; Joan Maurel
Journal:  Int J Mol Sci       Date:  2021-05-09       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.